Literature DB >> 8881251

Trisacryl gelatin microspheres for therapeutic embolization, II: preliminary clinical evaluation in tumors and arteriovenous malformations.

R Beaujeux1, A Laurent, M Wassef, A Casasco, Y P Gobin, A Aymard, D Rüfenacht, J J Merland.   

Abstract

PURPOSE: To evaluate an embolic agent that is precisely calibrated, perfectly spherical in shape, and soft but nonresorbable for use in the embolization of vascular disease of the head, neck, and spine in humans.
METHODS: We used supple, hydrophilic, and calibrated trisacryl gelatin microspheres 200, 400, 600, 800 and 1000 microns in diameter for superselective embolization in 105 patients (27 tumors, 14 facial arteriovenous malformations [AVMs], 37 spinal cord AVMs, 21 cerebral AVMs, and 6 miscellaneous diseases). We used particles in 200 to 600 microns in diameter for tumors and for facial AVMs, particles 400 to 600 microns in diameter for spinal cord AVMs, and particles over 1000 micros in diameter for cerebral AVMs.
RESULTS: Delivery of the embolic material was easy: microspheres did not aggregate and catheters did not become obstructed by particles. It was possible to control the embolization through precise accounting of the amount of microspheres and matching of the particle size to the size of the pathologic vascular network.
CONCLUSION: The microspheres are easy to use and allow precise control of the embolization procedure. Their physical characteristics make them a safe embolic agent.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8881251      PMCID: PMC8338004     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  20 in total

1.  The utility of the microcrystalline cellulose sphere as a particulate embolic agent: an experimental study.

Authors:  Y Kai; J Hamada; M Morioka; T Todaka; S Hasegawa; Y Ushio
Journal:  AJNR Am J Neuroradiol       Date:  2000 Jun-Jul       Impact factor: 3.825

2.  Newly developed embolic material mesosphere and titanium. Experimental and clinical studies.

Authors:  Y Konishi; E Sato; A Shimada; Y Shiokawa; I Saito; Y Kimura
Journal:  Interv Neuroradiol       Date:  2008-06-09       Impact factor: 1.610

3.  Perspective: Flicking with flow: Can microfluidics revolutionize the cancer research?

Authors:  Tamal Das; Suman Chakraborty
Journal:  Biomicrofluidics       Date:  2013-01-31       Impact factor: 2.800

4.  An overview of embolic agents.

Authors:  Sandeep Vaidya; Kathleen R Tozer; Jarvis Chen
Journal:  Semin Intervent Radiol       Date:  2008-09       Impact factor: 1.513

5.  Embolization in the head and neck.

Authors:  Daniel Cooke; Basavaraj Ghodke; Sabareesh Kumar Natarajan; Danial Hallam
Journal:  Semin Intervent Radiol       Date:  2008-09       Impact factor: 1.513

6.  Pharmaceuticals for Intra-arterial Therapy.

Authors:  Aalpen A Patel; Jeffery A Solomon; Michael C Soulen
Journal:  Semin Intervent Radiol       Date:  2005-06       Impact factor: 1.513

7.  Transcatheter arterial embolization of hypervascular tumors with HepaSphere: prospective multicenter open label clinical trial of microspheres in Japan.

Authors:  Takao Hiraki; Jun Koizumi; Yasuaki Arai; Yasuo Sakurai; Hiromitsu Kumada; Yoshihiro Nambu; Shinichi Hori
Journal:  Jpn J Radiol       Date:  2015-06-26       Impact factor: 2.374

8.  Unexpected complications with head and neck hydrogel microsphere particle embolization: A case series and a technical note.

Authors:  Naim N Khoury; Pierre-Olivier Champagne; Marc Kotowski; Jean Raymond; Daniel Roy; Alain Weill
Journal:  Interv Neuroradiol       Date:  2016-10-22       Impact factor: 1.610

9.  Clinical evaluation of cellulose porous beads for the therapeutic embolization of meningiomas.

Authors:  Y Kai; J-I Hamada; M Morioka; S Yano; H Nakamura; K Makino; T Mizuno; H Takeshima; J-I Kuratsu
Journal:  AJNR Am J Neuroradiol       Date:  2006-05       Impact factor: 3.825

10.  Effect of renal embolization with trisacryl and PAVc.

Authors:  Leandro de Assis Barbosa; Jose Guilherme Mendes Pereira Caldas; Mario Luiz Conti; Denise Maria Avancini Costa Malheiros; Francisco Ferreira Ramos
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.